Abigail Louise Higgins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Abigail Louise Higgins has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Chiao-Yin Lee
UCL Queen Square Institute of Neurology, University College London 4 Department of Clinical and Movement Neurosciences London
2 shared publications - Marco Toffoli
Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London
2 shared publications Sofia Koletsi
Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, United Kingdom
2 shared publicationsStephen Mullin
Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, United Kingdom
2 shared publicationsAnthony H V Schapira
Department of Clinical and Movement Neurosciences, University College London, Queen Square Institute of Neurology, London, United Kingdom
1 shared publicationAnthony H. V. Schapira
Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 6 July 2022
- Published by Springer Nature in Communications Biology
- Vol. 5 (1) , 1-10
Comprehensive short and long read sequencing analysis for the Gaucher and Parkinson’s disease-associated GBA gene
GBA variants carriers are at increased risk of Parkinson’s disease (PD) and Lewy body dementia (LBD). The presence of pseudogene GBAP1 predisposes to structural variants, complicating genetic analysis. We present two methods to resolve recombinant alleles and other variants in GBA: Gauchian, a tool for short-read, whole-genome sequencing data analysis, and Oxford Nanopore sequencing after PCR enrichment. Both methods were concordant for 42 samples carrying a range of recombinants and GBAP1-related mutations, and Gauchian outperformed the GATK Best Practices pipeline. Applying Gauchian to sequencing of over 10,000 individuals shows that copy number variants (CNVs) spanning GBAP1 are relatively common in Africans. CNV frequencies in PD and LBD are similar to controls. Gains may coexist with other mutations in patients, and a modifying effect cannot be excluded. Gauchian detects more GBA variants in LBD than PD, especially severe ones. These findings highlight the importance of accurate GBA analysis in these patients.
- 6 July 2022
- Published by Springer Nature in Communications Biology
- Vol. 5 (1) , 1-10
Open AccessComprehensive short and long read sequencing analysis for the Gaucher and Parkinson’s disease-associated GBA gene
GBA variants carriers are at increased risk of Parkinson’s disease (PD) and Lewy body dementia (LBD). The presence of pseudogene GBAP1 predisposes to structural variants, complicating genetic analysis. We present two methods to resolve recombinant alleles and other variants in GBA: Gauchian, a tool for short-read, whole-genome sequencing data analysis, and Oxford Nanopore sequencing after PCR enrichment. Both methods were concordant for 42 samples carrying a range of recombinants and GBAP1-related mutations, and Gauchian outperformed the GATK Best Practices pipeline. Applying Gauchian to sequencing of over 10,000 individuals shows that copy number variants (CNVs) spanning GBAP1 are relatively common in Africans. CNV frequencies in PD and LBD are similar to controls. Gains may coexist with other mutations in patients, and a modifying effect cannot be excluded. Gauchian detects more GBA variants in LBD than PD, especially severe ones. These findings highlight the importance of accurate GBA analysis in these patients.
- Open Access
- 20 October 2021
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 11 (6) , 451-458
The Remote Assessment of Parkinsonism Supporting the Ongoing Development of Interventions in Gaucher Disease
Mutations in GBA which are causative of Gaucher disease in their biallelic form, are the most common genetic risk factor for Parkinson's disease (PD). The diagnosis of PD relies upon clinically def... Lay abstract Changes in a gene called GBA cause a rare condition called Gaucher disease and are the most common genetic risk factor for Parkinson's disease (PD). To diagnose PD, patients must show ...
- 20 October 2021
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 11 (6) , 451-458
Open AccessThe Remote Assessment of Parkinsonism Supporting the Ongoing Development of Interventions in Gaucher Disease
Mutations in GBA which are causative of Gaucher disease in their biallelic form, are the most common genetic risk factor for Parkinson's disease (PD). The diagnosis of PD relies upon clinically def... Lay abstract Changes in a gene called GBA cause a rare condition called Gaucher disease and are the most common genetic risk factor for Parkinson's disease (PD). To diagnose PD, patients must show ...
- Open Access
The Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher Disease – Study Protocol
Mutations in GBA which are causative of Gaucher disease in their biallelic form, are the most common genetic risk factor for Parkinson disease. The diagnosis of Parkinson disease relies upon clinically defined motor features which appear after irreversible neurodegeneration. Prodromal symptoms of Parkinson disease may provide a means to predict latent pathology, years before the onset of motor features. Previous work has reported prodromal features of Parkinson disease in GBA mutation carriers, however this has been insufficiently sensitive to identify those that will develop Parkinson disease. The Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher Disease (RAPSODI) study assesses a large cohort of GBA mutation carriers, to aid development of procedures for earlier diagnosis of Parkinson disease. Summary Points: The therapeutic focus for Parkinson disease is currently symptomatic, rather than disease-modifying or neuroprotective. Non-motor prodromal features of Parkinson disease may precede the motor symptoms required for clinical diagnosis by several years. GBA mutations, which are associated with Gaucher disease in their biallelic form, have emerged as the most common genetic risk factor for Parkinson Disease. GBA associated PD displays a slightly exaggerated phenotype, including earlier age of onset, enhanced cognitive decline, more severe affective disturbances, and a greater likelihood of manifesting REM Sleep Behaviour Disorder, hyposmia and autonomic dysfunction. The RAPSODI GD study is an annual remote assessment which aims to define the clinical prodrome of PD in a large cohort of GBA mutation carriers, to accurately predict clinical diagnosis. The secondary objectives of RAPSODI GD are to risk stratify homozygote and heterozygote GBA mutation carriers for PD risk, understand the variable penetrance of the GBA associated PD phenotype, and create a platform for the future evaluation of biomarkers of disease. The putative implication of the RAPSODI GD study is to contribute towards earlier diagnosis of GBA associated PD, to provide a timeframe for delivering neuroprotective interventions. Defining prodromal PD in GBA carriers may have wider implications for sporadic PD.
Open AccessThe Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher Disease – Study Protocol
Mutations in GBA which are causative of Gaucher disease in their biallelic form, are the most common genetic risk factor for Parkinson disease. The diagnosis of Parkinson disease relies upon clinically defined motor features which appear after irreversible neurodegeneration. Prodromal symptoms of Parkinson disease may provide a means to predict latent pathology, years before the onset of motor features. Previous work has reported prodromal features of Parkinson disease in GBA mutation carriers, however this has been insufficiently sensitive to identify those that will develop Parkinson disease. The Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher Disease (RAPSODI) study assesses a large cohort of GBA mutation carriers, to aid development of procedures for earlier diagnosis of Parkinson disease. Summary Points: The therapeutic focus for Parkinson disease is currently symptomatic, rather than disease-modifying or neuroprotective. Non-motor prodromal features of Parkinson disease may precede the motor symptoms required for clinical diagnosis by several years. GBA mutations, which are associated with Gaucher disease in their biallelic form, have emerged as the most common genetic risk factor for Parkinson Disease. GBA associated PD displays a slightly exaggerated phenotype, including earlier age of onset, enhanced cognitive decline, more severe affective disturbances, and a greater likelihood of manifesting REM Sleep Behaviour Disorder, hyposmia and autonomic dysfunction. The RAPSODI GD study is an annual remote assessment which aims to define the clinical prodrome of PD in a large cohort of GBA mutation carriers, to accurately predict clinical diagnosis. The secondary objectives of RAPSODI GD are to risk stratify homozygote and heterozygote GBA mutation carriers for PD risk, understand the variable penetrance of the GBA associated PD phenotype, and create a platform for the future evaluation of biomarkers of disease. The putative implication of the RAPSODI GD study is to contribute towards earlier diagnosis of GBA associated PD, to provide a timeframe for delivering neuroprotective interventions. Defining prodromal PD in GBA carriers may have wider implications for sporadic PD.